ReviewBlood advances2026
Burkitt lymphoma: current understanding, unmet needs, and research directions.
Review in Blood advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
abstractBurkitt lymphoma (BL) is an aggressive B-cell lymphoma historically classified into endemic, sporadic, or immunodeficiency-associated BL based on clinical and epidemiological features. Recent genomic and epigenomic studies have refined this framework, distinguishing Epstein-Barr virus (EBV)-positive and EBV-negative BL molecular subtypes that cut across traditional clinical and epidemiological categories and exhibit distinct biological profiles. In high-income countries (HICs), BL is highly curable with intensive multiagent chemotherapy and antibody-based therapy. In contrast, survival in sub-Saharan Africa rarely exceeds 50%, reflecting diagnostic delays, limited access to effective treatment, and challenges in supportive care. This review summarizes the advances in BL epidemiology, molecular biology, diagnosis, and treatment, highlighting how genomic insights have identified novel biomarkers for earlier detection and monitoring, as well as potential targeted therapies with reduced toxicity. These advances present opportunities to develop scalable diagnostic tools and tailored therapeutic strategies to narrow survival disparities, particularly in resource-limited settings, where most patients occur, and among adults and patients with relapsed or refractory BL in HICs. We also outline key unanswered questions in BL epidemiology and pathogenesis, discuss opportunities for translational research, and emphasize the need for improved model systems to study therapeutic resistance to close the survival gap.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.